Lih En Hong, Mihir D Wechalekar, Monika M Kutyna, Annabelle Small, Kelly Lim, Chloe Al Thompson-Peach, Joule J Li, Rakchha Chhetri, Hamish S Scott, Anna L Brown, Christopher N Hahn, David T Yeung, Salvia Sajid, Nirmal Robinson, Ranjeny Thomas, Susan Branford, Richard J J D'Andrea, Saumya E E Samaraweera, Mrinal M Patnaik, Susanna Proudman, Daniel Thomas, Chung Hoow Kok, Mithun Vinod Shah, Devendra K Hiwase
High prevalence of IDH-mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity and pro-inflammatory microenvironment, suggests causative association between IDH-mutations and seronegative RA. Our findings merit investigation of IDH-inhibitors as therapeutics for seronegative IDH-mutated RA.
March 8, 2024: Blood